Training: What U.S. Clinicians Need to Know About Chagas Disease

Training overview

Program description

This enduring activity will inform healthcare providers about Chagas disease including manifestations and transmission modes with example cases to relate to their own patient experiences.

Faculty/credentials

Paul T. Cantey, MD, MPH, Parasitic Diseases Branch Chief, CDC, Center for Global Health, Division of Parasitic Diseases and Malaria

Susan P. Montgomery, DVM, MPH, Veterinary Medical Officer/Epidemiology Team Lead, CDC, Center for Global Health, Division of Parasitic Diseases and Malaria, Parasitic Diseases Branch

Training objectives

At the conclusion of the session, the participant should be able to:

1. Describe Chagas disease epidemiology.
2. Describe the clinical manifestations of Chagas disease.
3. Describe how to diagnose Chagas disease
4. Describe the treatment options for Chagas disease.
5. Using information presented in a case study demonstrate how to manage a patient with Chagas disease.
6. Describe the importance of the health care team to address Chagas disease in U.S. patients.

Target audience

Continuing Education (CE)

Instructions for obtaining CE

To receive CE for WB4621R- Chagas Disease in the U.S. (What United States Health Care Providers Need to Know About Chagas Disease), please visit CDC TRAIN and search for the course in the Course Catalog using WB4621R. Follow the steps below by September 2, 2027.

1. Register for and complete the course.

2. Pass the post-assessment at 80%.

3. Complete the evaluation.

4. Visit Your Learning to access your certificates and transcript.

Accreditation statements

In support of improving patient care, The Centers for Disease Control and Prevention is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

CME: The Centers for Disease Control and Prevention designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CNE: The Centers for Disease Control and Prevention designates this activity for 1.0 nursing contact hours.

Disclosure

In compliance with continuing education requirements, all planners and presenters must disclose all financial relationships, in any amount, with ineligible companies during the previous 24 months as well as any use of unlabeled product(s) or products under investigational use.

CDC, our planners, and content experts wish to disclose they have no financial relationship(s) with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.

Content will not include any discussion of the unlabeled use of a product or a product under investigational use with the exception of Dr. Cantey and Dr. Montgomery's discussion of benznidazole and nifurtimox (Lampit®). They will be discussing use of these two drugs to treat adult patients.

CDC did not accept financial or in-kind support from ineligible companies for this continuing education activity.